Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.64 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.64 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.64 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CRACR2A | Q9BSW2 | 7/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7234017 | 0.84 | TP53 (0.86) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7325708 | 0.81 | ORAI1 (0.79) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7327754 | 0.81 | CRACR2A (0.74) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL5546563 | 0.81 | ORAI1 (0.61) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7319568 | 0.81 | ORAI1 (0.64) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7327208 | 0.80 | ORAI1 (0.64) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7328795 | 0.80 | TP53 (0.69) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7315257 | 0.79 | ORAI1 (0.79) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7326340 | 0.79 | ORAI1 (0.73) | ORAI1TRPC3TRPC1STIM1TP53 | |
| SCHEMBL7326499 | 0.79 | ORAI1 (0.69) | ORAI1TRPC3TRPC1STIM1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131484-A1 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE | ASTELLAS PHARMA INC (JP) | 2009-05-21 | — | — | US | claimed |
| EP-1875925-A1 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE | Astellas Pharma Inc. (JP) | 2008-01-09 | — | — | EP | claimed |
| US-7309710-B2 | Crystals | ASTELLAS PHARMA INC. (JP) | 2007-12-18 | — | — | US | claimed |
| US-20060069130-A1 | Novel crystals | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | claimed |
| EP-1548015-A1 | NOVEL CRYSTALS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-06-29 | — | — | EP | claimed |
| US-20090131484-A1 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE | ASTELLAS PHARMA INC (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1875925-A1 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE | Astellas Pharma Inc. (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7309710-B2 | Crystals | ASTELLAS PHARMA INC. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-7309710-B2 | Crystals | ASTELLAS PHARMA INC. (JP) | 2007-12-18 | — | — | US | disclosed |
| US-20060069130-A1 | Novel crystals | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| US-20060069130-A1 | Novel crystals | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1548015-A1 | NOVEL CRYSTALS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1548015-A1 | NOVEL CRYSTALS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004020433-A1 | NOVEL CRYSTALS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069130-A1 | Novel crystals | CACNA1B, ORAI1, RYR2 | ORAI1 2/4885TRPC3 29/4885TRPC1 24/4885 |
| US-20090131484-A1 | PREVENTIVE OR REMEDY FOR BOWEL DISEASE | ORAI1, SI, CACNA1C | ORAI1 1/4885TRPC3 27/4885TRPC1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.